Clinical trial · Observational

Testosterone Implants and the Incidence of Breast Cancer

Testosterone Implants and the Incidence of Breast Cancer RETROSPECTIVE CHART REVIEW

NCT03768258CI-TRIAL-00053718TIBCaPcompletedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

This current chart review study was designed to investigate the incidence of breast cancer in women treated with subcutaneous testosterone therapy for symptoms of hormone deficiency.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Breast Cancer	Malignant Breast Neoplasm	CURATED_EXACT	0.92

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Testosterone Implant	Drug	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
Incidence of invasive breast cancer
timeFrame
10-year results
description
The incidence of invasive breast cancer in women treated with testosterone therapy

Secondary outcomes (1)

measure
Incidence of ductal carcinoma in situ
timeFrame
10-year results
description
The incidence of DCIS in women treated with testosterone therapy

Eligibility

Eligibility (as posted)

Sex: Female
Minimum age: 24 Years
Maximum age: 92 Years

Show eligibility criteria text

Inclusion Criteria:

* Female patients treated between March 2008 - March 2013
* Women who received at least two testosterone pellet insertion procedures
* Women previously accrued to the prospective cohort study

Exclusion Criteria:

* Pre-existing breast cancer
* Women who received a single testosterone pellet insertion

References

Publications (1)

RESULTGlaser RL, York AE, Dimitrakakis C. Incidence of invasive breast cancer in women treated with testosterone implants: a prospective 10-year cohort study. BMC Cancer. 2019 Dec 30;19(1):1271. doi: 10.1186/s12885-019-6457-8. PMID 31888528